Inferior survival and frequent hepatic dysfunction in non-Hodgkin’s lymphoma patients with HBV infection: a systematic review and meta-analysis

Reference

• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.
   PubMed Web of Science ®Google Scholar
• de The G. Viruses and human cancers: challenges for preventive strategies. Environ Health Perspect. 1995;103(suppl 8):269–273.
   PubMedGoogle Scholar
• Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med. 2004;350:213–215.
   PubMed Web of Science ®Google Scholar
• Armand M, Besson C, Hermine O, et al. Hepatitis C virus - associated marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30:41–49.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Pontisso P, Vidalino L, Quarta S, et al. Biological and clinical implications of HBV infection in peripheral blood mononuclear cells. Autoimmun Rev. 2008;8:13–17.
   PubMed Web of Science ®Google Scholar
• Wang F, Yuan S, Teng KY, et al. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012;21:261–267.
   PubMed Web of Science ®Google Scholar
• Li M, Gan Y, Fan C, et al. Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies. J Viral Hepat. 2018;25:894–903.
   PubMed Web of Science ®Google Scholar
• Deng L, Song Y, Young KH, et al. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget. 2015;6:25061–25073.
   PubMedGoogle Scholar
• Law MF, Lai HK, Chan HN, et al. The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma. Eur J Cancer Care (Engl). 2015;24:117–124.
   PubMed Web of Science ®Google Scholar
• Liu WP, Wang XP, Zheng W, et al. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leuk Lymphoma. 2016;57:1355–1362.
   PubMed Web of Science ®Google Scholar
• Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131:2670–2681.
   PubMed Web of Science ®Google Scholar
• Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115.
   PubMed Web of Science ®Google Scholar
• Zhao X, Guo X, Xing L, et al. HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. Cell Death Dis. 2018;9:61.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Chen FY, Zhong H. Meta-analysis of human leukocyte antigen genetic polymorphisms and susceptibility to chronic myelogenous leukemia in Chinese population. Leuk Res. 2011;35:1564–1570.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Miao L, Li YS, et al. Meta-analysis of the methylenetetrahydrofolate reductase C677 T polymorphism and susceptibility to Alzheimer's disease. Neurosci Res. 2010;68:142–150.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Zhu GQ, Shi KQ, et al. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7:30642–30658.
   PubMedGoogle Scholar
• Zhang MY, Zhu GQ, Zheng JN, et al. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. Expert Rev Anti Infect Ther. 2017;15:503–513.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li S, Guo W, et al. MYC gene rearrangements Are closely associated with poor survival of diffuse large B cell lymphoma with hepatitis B virus infection. Biomed Res Int. 2017;2017:1967648.
   PubMed Web of Science ®Google Scholar
• Xie W, Zhou D, Hu K, et al. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. Exp Ther Med. 2013;6:109–114.
   PubMed Web of Science ®Google Scholar
• Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agents Cancer. 2018;13:1–6, doi:10.1186/s13027-018-0215-4
   PubMed Web of Science ®Google Scholar
• Huang YH. Clinical characters and prognostic analysis of diffuse large B-cell lymphoma patients with hepatitis B virus infection [dissertation]. Peking Union Medical College; 2012
   Google Scholar
• Shan LZ, Song T, Wang HQ, et al. Clinical features and prognosis of HBsAg-positive patients with diffuse large B-cell lymphoma. J Pract Oncol. 2016;31:163–169.
   Google Scholar
• Feng Y, Wang XW, Liu XN, et al. Relationship of HBV infection and diffuse large B-cell lymphoma. Clin J Nosocomiology. 2016;26:2887–2889.
   Google Scholar
• Lim ST, Fei G, Quek R, et al. The relationship of hepatitis B virus infection and non-Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol. 2007;79:132–137.
   PubMed Web of Science ®Google Scholar
• Lv R. Clinical analysis of 112 cases of non-MALT marginal zone lymphoma [dissertation]. Chinese Academy of Medical Sciences & Peking Union Medical College;2015.
   Google Scholar
• Wang QX, Li JY, Ni QR, et al. Correlation study of hepatitis B virus infection and diffuse large B-cell lymphoma. Int J Virol. 2016;23:332–335.
   Google Scholar
• Wang Y, Wang H, Pan S, et al. Capable infection of hepatitis B virus in diffuse large B-cell lymphoma. J Cancer. 2018;9:1575–1581.
   PubMed Web of Science ®Google Scholar
• Wei HM, Luo CY, Liu KP, et al. The relevance of HBV infection to clinic pathological characteristics and prognosis of diffused large B-cell lymphoma. Chin J Gerontol. 2015;9:2455–2456.
   Google Scholar
• Wei Z, Zou S, Li F, et al. HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China. Med Oncol. 2014;31:845.
   PubMed Web of Science ®Google Scholar
• Yi S, Yan Y, Xiong W, et al. Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region. Oncotarget. 2017;8:98757–98770.
   PubMedGoogle Scholar
• Zhang Y. The relationship between hepatitis B virus infection and diffuse large-B celllymphoma [dissertation]. Zhejiang University; 2012.
   Google Scholar
• Zhang Y, Yang MZ. The clinical features, BCL-2, CMYC protein expression and prognosis of the hepatitis B virus-associated diffuse large B-cell lymphoma. Acta Univ Med Anhui. 2017;52:570–574.
   Google Scholar
• Wang L, Wu-Xiao ZJ, Chen XQ, et al. Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma. Leuk Lymphoma. 2015;56:936–941.
   PubMed Web of Science ®Google Scholar
• Li WB. Clinical characteristics and prognosis of diffuse large B-cell lymphoma [dissertation]. Shantou University; 2010.
   Google Scholar
• Dalia S, Chavez J, Castillo JJ, et al. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013;37:1107–1115.
   PubMed Web of Science ®Google Scholar
• Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827–834.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117:1792–1798.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Spada E, Mele A, et al. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res. 2012;2:18–28.
   PubMedGoogle Scholar
• Nath A, Agarwal R, Malhotra P, et al. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Intern Med J. 2010;40:633–641.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Am J Clin Oncol. 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Gao G, Liang X, Jiang J, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol. 2010;49:3–12. doi:10.3109/02841860903150502
   PubMed Web of Science ®Google Scholar
• Cardenas MG, Yu W, Beguelin W, et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest. 2016;126:3351–3362. doi:10.1172/jci85795.
   PubMed Web of Science ®Google Scholar
• Rong X, Wang H, Ma J, et al. Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review. J Cancer. 2019;10:3450–3458.
   PubMed Web of Science ®Google Scholar
• Park JH, Yoon DH, Kim DY, et al. The highest prognostic impact of LDH among International Prognostic indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. Ann Hematol. 2014;93:1755–1764.
   PubMed Web of Science ®Google Scholar
• He X, Chen Z, Fu T, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL rituximab-CHOP consortium program. Blood. 2013;121:4021–4031; quiz 4250.
   PubMed Web of Science ®Google Scholar
• Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol. 2008;87:475–480.
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–6557.
   PubMed Web of Science ®Google Scholar